SCHEMBL415894

SCHEMBL415894

CCOC(=O)c1cn(-c2ccc(F)cn2)nc1I

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
LMNA P02545 4/20 0.44
JMJD6 Q6NYC1 1/20 0.41
KDM4E B2RXH2 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
POLB P06746 1/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.40
P2RX3 P56373 1/20 0.40
PDE4B Q07343 1/20 0.39
GAA P10253 3/20 0.39
GLA P06280 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
MAPK1 P28482 1/20 0.38
GABRA2 P47869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL416852 0.79 NPC1 (0.41) NPC1RAB9ALMNAJMJD6KDM4E
SCHEMBL16648743 0.77 EGLN1 (0.46) NPC1RAB9ALMNAKDM4ESMN1; SMN2
SCHEMBL13933902 0.77 JMJD6 (0.44) NPC1RAB9ALMNAJMJD6KDM4E
SCHEMBL16827637 0.76 LMNA (0.49) NPC1RAB9ALMNASMN1; SMN2ALDH1A1
SCHEMBL19120519 0.75 GRIA1 (0.33) CSNK1D
SCHEMBL20028758 0.75 NPSR1 (0.64) NPC1RAB9AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL6035327 0.73 SMN1; SMN2 (0.61) NPC1RAB9ALMNAKDM4ESMN1; SMN2
SCHEMBL19120833 0.72 HTR1A (0.33)
SCHEMBL645580 0.72 TSHR (0.47) NPC1RAB9ALMNAJMJD6KDM4E
SCHEMBL20098715 0.71 SMN1; SMN2 (0.65) NPC1RAB9ALMNAKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2410858-B1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2016-09-07 EP disclosed
US-8946231-B2 P2X3, receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2015-02-03 US disclosed
US-20120021074-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME CORP. (US) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120021074-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 NPC1 4049/4885RAB9A 3810/4885LMNA 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.